EA038703B1 - Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения - Google Patents

Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения Download PDF

Info

Publication number
EA038703B1
EA038703B1 EA201890039A EA201890039A EA038703B1 EA 038703 B1 EA038703 B1 EA 038703B1 EA 201890039 A EA201890039 A EA 201890039A EA 201890039 A EA201890039 A EA 201890039A EA 038703 B1 EA038703 B1 EA 038703B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
tau protein
seq
antibody
acid sequence
Prior art date
Application number
EA201890039A
Other languages
English (en)
Russian (ru)
Other versions
EA201890039A1 (ru
Inventor
Ян Торлейф Педерсен
Ларс Остергаард Педерсен
Джастус Клаус Альфред Дачсел
Эйодеджи Абдур-Рашид Асуни
Нина Розенквист
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1512211.2A external-priority patent/GB201512211D0/en
Priority claimed from GBGB1518375.9A external-priority patent/GB201518375D0/en
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA201890039A1 publication Critical patent/EA201890039A1/ru
Publication of EA038703B1 publication Critical patent/EA038703B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
EA201890039A 2015-07-13 2016-07-12 Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения EA038703B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1512211.2A GB201512211D0 (en) 2015-07-13 2015-07-13 Agents, uses and methods
GBGB1518375.9A GB201518375D0 (en) 2015-10-16 2015-10-16 Agents,uses and methods
PCT/EP2016/066470 WO2017009308A2 (en) 2015-07-13 2016-07-12 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201890039A1 EA201890039A1 (ru) 2018-08-31
EA038703B1 true EA038703B1 (ru) 2021-10-07

Family

ID=56557664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890039A EA038703B1 (ru) 2015-07-13 2016-07-12 Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Country Status (32)

Country Link
US (4) US10196439B2 (enExample)
EP (1) EP3322442A2 (enExample)
JP (1) JP6878395B2 (enExample)
KR (1) KR20180030047A (enExample)
CN (1) CN107847595B (enExample)
AU (1) AU2016292892B2 (enExample)
BR (1) BR112018000769A2 (enExample)
CA (1) CA2990555A1 (enExample)
CL (1) CL2018000096A1 (enExample)
CO (1) CO2017013318A2 (enExample)
CR (1) CR20180026A (enExample)
DO (1) DOP2018000012A (enExample)
EA (1) EA038703B1 (enExample)
EC (1) ECSP18002644A (enExample)
GE (1) GEP20227369B (enExample)
HK (1) HK1254357A1 (enExample)
IL (1) IL256791B (enExample)
JO (1) JO3711B1 (enExample)
MA (1) MA42446A (enExample)
MX (1) MX392396B (enExample)
NI (1) NI201800005A (enExample)
NZ (1) NZ738595A (enExample)
PE (1) PE20180607A1 (enExample)
PH (1) PH12018500062A1 (enExample)
RU (1) RU2727911C2 (enExample)
SG (1) SG10202101343RA (enExample)
SV (1) SV2018005611A (enExample)
TN (1) TN2017000541A1 (enExample)
TW (1) TWI741987B (enExample)
UA (1) UA123862C2 (enExample)
WO (1) WO2017009308A2 (enExample)
ZA (1) ZA201800070B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
EP3303386B1 (en) 2015-06-05 2024-08-28 Genentech, Inc. Anti-tau antibodies and methods of use
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
RU2760875C1 (ru) * 2016-07-12 2021-12-01 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
US11590304B2 (en) 2016-08-15 2023-02-28 The Board Of Regents Of The University Of Texas System Volume control device for manually operated resuscitator and ventilation apparatus and method of use
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
AU2017373889B2 (en) 2016-12-07 2025-01-02 Ac Immune Sa Anti-Tau antibodies and methods of use
CN110248959B (zh) 2016-12-07 2023-06-30 基因泰克公司 抗tau抗体和使用方法
EP3565836A1 (en) 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
TWI750419B (zh) 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
CN111465410B (zh) 2017-12-14 2022-10-25 H.隆德贝克有限公司 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット PDE1阻害剤としてのピラゾロ[3,4-b]ピリジン及びイミダゾ[1,5-b]ピリダジン
KR20200116105A (ko) * 2018-02-01 2020-10-08 얀센 백신스 앤드 프리벤션 비.브이. 타우에 특이적으로 결합하는 결합 분자
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
MA55305A (fr) 2019-03-11 2022-01-19 Janssen Biotech Inc Anticorps bispécifiques anti-v béta 17/anti-cd123
JP2022527087A (ja) 2019-03-28 2022-05-30 ハー・ルンドベック・アクチエゼルスカベット タウオパチーを診断するためのpS396アッセイの使用
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
SG10201908922UA (en) * 2019-09-25 2021-04-29 Sengenics Corp Pte Ltd Identification of health status in the elderly using immunological biomarkers
MX2022012752A (es) 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
WO2022035722A1 (en) 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
WO2022056192A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
US20250298039A1 (en) * 2020-11-12 2025-09-25 Children`S Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
CA3205586A1 (en) 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
EP4543473A1 (en) 2022-06-22 2025-04-30 Voyager Therapeutics, Inc. Tau binding compounds
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
JP2025535871A (ja) * 2022-09-26 2025-10-30 ウォーターストーン ファーマシューティカルズ(ウーハン)カンパニー,リミティド Fc-長鎖脂肪酸鎖を含む超長作用型プラットフォーム
CN116794328A (zh) * 2023-06-20 2023-09-22 南京鼓楼医院 一种基于多位点的高灵敏磷酸化Tau蛋白检测方法
CN116754776A (zh) * 2023-06-20 2023-09-15 南京鼓楼医院 一种基于S396与S404位点的高灵敏磷酸化Tau蛋白检测方法
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002027017A2 (en) * 2000-09-27 2002-04-04 Biosource International Method for quantifying phosphokinase activity on proteins
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
WO2013050567A1 (en) * 2011-10-07 2013-04-11 Ac Immune S.A. Phosphospecific antibodies recognising tau

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991001754A1 (en) 1989-08-09 1991-02-21 Rhodes Buck A Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
WO1993011231A1 (en) 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
MXPA01007895A (es) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
HK1049014A1 (zh) 1999-07-29 2003-04-25 Medarex, Inc. 抗her2/neu的人类单克隆抗体
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007019273A2 (en) 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP4218794A3 (en) 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
KR20120092139A (ko) 2009-10-26 2012-08-20 오츠카 세이야쿠 가부시키가이샤 벤즈아제핀 화합물
LT2627672T (lt) 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
SMT201800109T1 (it) * 2011-09-19 2018-05-02 Axon Neuroscience Se Terapia a base di proteine e diagnosi di una patologia mediata da tau nella malattia di alzheimer
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
WO2014008404A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン,インコーポレイティド タウオパチーの処置方法
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
EP2986713A1 (en) * 2013-04-16 2016-02-24 Glykos Finland Oy A method for generating induced pluripotent stem cells
US10132818B2 (en) 2014-07-08 2018-11-20 New York University Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
RU2760875C1 (ru) 2016-07-12 2021-12-01 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3565836A1 (en) 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002027017A2 (en) * 2000-09-27 2002-04-04 Biosource International Method for quantifying phosphokinase activity on proteins
WO2012045882A2 (en) * 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
WO2013050567A1 (en) * 2011-10-07 2013-04-11 Ac Immune S.A. Phosphospecific antibodies recognising tau

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
1 January 2006, article ANNYMOUS: "Anti-phospho-Tau (pSer199/202); Data sheet; Cat.No. T6819", XP055342158 *
1 January 2010, article ANONYMOUS: "Tau Phosphorylation Site-Specific Antibody Sampler (Containing Tau pS199, pT205, pT231, pS262, pS356, pS396, pS404, pS409, pS422 Rabbit Polyclonal & Tau [TAU-5] Monoclonal Antibodies, Unconjugated) PRODUCT ANALYSIS SHEET", XP055342248 *
15 September 2011, NOVEX , article ANONYMOUS: "Tau [pS199] ABfinity ™ Recombinant Rabbit Monoclonal Antibody – Purified; Cat.No. 701054", pages: 1 - 2, XP055342152 *
Anonymous: "Application Abreviews Notes", 26 March 2014 (2014-03-26), XP055342014, Retrieved from the Internet: URL:http://www.abcam.com/Tau-phospho-S199- antibody-EPR2401Y-ab81268.pdf [retrieved on 2017-02-03] the whole document *
Anonymous: "Mouse anti-Phospho-Tau 396 Mouse anti-Phospho-Tau 396; Catalog No. 35-5300", invitrogen cataologue Catalog No. 35-5300, 1 October 2008 (2008-10-01), XP055308498, Retrieved from the Internet: URL:https://tools.thermofisher.com/content/sfs/manuals/35-5300_Mouse anti-Phospho-Tau 396 Rev 1008.pdf [retrieved on 2016-10-07] the whole document *
Anonymous: "Product datasheet Anti-Tau (phospho S396) antibody [EPR2731] ab109390", abcam product catalogue, 1 January 2014 (2014-01-01), XP055308426, Retrieved from the Internet: URL:http://www.abcam.com/Tau-phospho-S396- antibody-EPR2731-ab109390.pdf [retrieved on 2016-10-06] the whole document *
DAVID SINGER ; DANIELA VOLKE ; RALF HOFFMANN: "Characterization of Phosphorylation Dependent Antibodies To Study the Phosphorylation Status of the Tau Protein", INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, KLUWER ACADEMIC PUBLISHERS, DO, vol. 11, no. 4, 1 December 2005 (2005-12-01), Do , pages 279 - 289, XP019287635, ISSN: 1573-3904 *
JEFFEREY R JACKSON: "In Vitro Antibody Maturation Improvement of a High Affinity, Neutralizing Antibody Against IL-1 beta", THE JOURNAL OF IMMUNOLOGY, vol. 154, 1 January 1995 (1995-01-01), pages 3310 - 3319, XP055033979 *
JOËLLE ROSSEELS, JEFF VAN DEN BRANDE, MARIE VIOLET, DIRK JACOBS, PIERRE GROGNET, JUAN LOPEZ, ISABELLE HUVENT, MARINA CALDARA, ERWI: "Tau Monoclonal Antibody Generation Based on Humanized Yeast Models", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 290, no. 7, 13 February 2015 (2015-02-13), US , pages 4059 - 4074, XP055250974, ISSN: 0021-9258, DOI: 10.1074/jbc.M114.627919 *
MICHAEL A. BRISTER, ANIL K. PANDEY, AGATA A. BIELSKA, NEAL J. ZONDLO: "OGlcNAcylation and Phosphorylation Have Opposing Structural Effects in tau: Phosphothreonine Induces Particular Conformational Order", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, vol. 136, no. 10, 12 March 2014 (2014-03-12), pages 3803 - 3816, XP055308062, ISSN: 0002-7863, DOI: 10.1021/ja407156m *
RUDIKOFF S, ET AL.: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/pnas.79.6.1979 *
YEE WAH WONG, ET AL: "Structural Requirements for a Specificity Switch and for Maintenance of Affinity Using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Determining Region", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 160, 1 January 1998 (1998-01-01), US , pages 5990 - 5997, XP007916801, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
NI201800005A (es) 2018-10-19
CA2990555A1 (en) 2017-01-19
US20210206843A1 (en) 2021-07-08
US20190177401A1 (en) 2019-06-13
CR20180026A (es) 2018-03-08
JP6878395B2 (ja) 2021-05-26
RU2018100822A3 (enExample) 2019-12-26
GEP20227369B (en) 2022-04-11
IL256791A (en) 2018-03-29
PH12018500062A1 (en) 2018-07-09
US20170015738A1 (en) 2017-01-19
TN2017000541A1 (en) 2019-04-12
US20200190178A1 (en) 2020-06-18
US11739140B2 (en) 2023-08-29
SV2018005611A (es) 2018-02-23
UA123862C2 (uk) 2021-06-16
JO3711B1 (ar) 2021-01-31
DOP2018000012A (es) 2018-02-28
NZ738595A (en) 2022-07-01
TW201716436A (zh) 2017-05-16
AU2016292892A1 (en) 2018-01-18
IL256791B (en) 2022-09-01
WO2017009308A2 (en) 2017-01-19
ECSP18002644A (es) 2018-03-31
US10562962B2 (en) 2020-02-18
WO2017009308A3 (en) 2017-04-06
CN107847595B (zh) 2021-09-24
ZA201800070B (en) 2019-04-24
MX2018000505A (es) 2018-04-30
MX392396B (es) 2025-03-24
EA201890039A1 (ru) 2018-08-31
EP3322442A2 (en) 2018-05-23
RU2018100822A (ru) 2019-08-13
BR112018000769A2 (pt) 2018-09-25
MA42446A (fr) 2018-05-23
KR20180030047A (ko) 2018-03-21
PE20180607A1 (es) 2018-04-09
CN107847595A (zh) 2018-03-27
CO2017013318A2 (es) 2018-05-21
RU2727911C2 (ru) 2020-07-24
SG10202101343RA (en) 2021-03-30
TWI741987B (zh) 2021-10-11
JP2018531580A (ja) 2018-11-01
HK1254357A1 (zh) 2019-07-19
AU2016292892B2 (en) 2021-11-18
CL2018000096A1 (es) 2018-07-06
US10934348B2 (en) 2021-03-02
US10196439B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
US11739140B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
US12129289B2 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
HK40059227A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.
HK40007700B (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
HK40007700A (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof